Abstract
Aim:
To investigate the metabolism of 3-cyanomethyl-4-methyl-DCK (CMDCK), a novel anti-HIV agent, by human liver microsomes (HLMs) and recombinant cytochrome P450 enzymes (CYPs).
Methods:
CMDCK was incubated with HLMs or a panel of recombinant cytochrome P450 enzymes including CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4, and 3A5. LC-ion trap mass spectrometry was used to separate and identify CMDCK metabolites. In the experiments with recombinant cytochrome P450 enzymes, specific chemical inhibitors combined with CYP antibodies were used to identify the CYP isoforms involved in CMDCK metabolism.
Results:
CMDCK was rapidly and extensively metabolized by HLMs. Its intrinsic hepatic clearance estimated from the in vitro data was 19.4 mL·min−1·kg−1, which was comparable to the mean human hepatic blood flow rate (20.7 mL·min−1·kg−1). The major metabolic pathway of CMDCK was oxidation, and a total of 14 metabolites were detected. CYP3A4 and 3A5 were found to be the principal CYP enzymes responsible for CMDCK metabolism.
Conclusion:
CMDCK was metabolized rapidly and extensively in human hepatic microsomes to form a number of oxidative metabolites. CYP3A4 and 3A5 were the predominant enzymes responsible for the oxidation of CMDCK.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
De Clercq E . Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009; 33: 307–20.
Kostova I, Raleva S, Genova P, Argirova R . Structure-activity relationships of synthetic coumarins as HIV-1 Inhibitors. Bioinorg Chem Appl 2006; 68274.
Huang L, Yuan X, Yu D, Lee KH, Chen CH . Mechanism of action and resistant profile of anti-HIV coumarin derivatives. Virology 2005; 332: 623–8.
Xie L, Zhao CH, Zhou T, Chen HF, Fan BT, Che XH, et al. Molecular modeling, design, synthesis, and biological evaluation of novel 3′,4′-dicamphanoyl-(+)-cis-khellactone (DCK) analogs as potent anti-HIV agents. Bioorg Med Chem 2005; 13: 6435–49.
Xie L, Guo HF, Lu H, Zhuang XM, Zhang AM, Wu G, et al. Development and preclinical studies of broad-spectrum anti-HIV agent (3′R,4′R)-3-cyanomethyl-4-methyl-3′,4′-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK). J Med Chem 2008; 51: 7689–96.
Obach RS . Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27: 1350–9.
Houston JB . Utility of in vitro drug metabolism data in prediction of in vivo metabolic clearance. Biochem Phannacol 1994; 47: 1469–79.
Davies B, Morris T . Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093–5.
Gerlowski LE, Jain RK . Physiologically based pharmacokinetic modeling: Principles and applications. J Pham Sci 1983; 72: 1103–27.
Rodrigues AD . Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999; 57: 465–80.
Yamazaki M, Suzuki H, Sugiyama Y . Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 1996; 13: 497–513.
Boxenbaum H . Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 1980; 8: 165–76.
Suzuki M, Li Y, Smith PC, Swenberg JA, Martin DM, Morris-Natschke SL, et al. Anti-AIDS agents 65: investigation of the in vitro oxidative metabolism of 3′,4′-Di-O-(−)-camphanoyl-(+)-cis-khellactone derivatives as potent anti-HIV agents. Drug Metab Dispos 2005; 33: 1588–92.
Masimirembwa CM, Bredberg U, Andersson TB . Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 2003; 42: 515–28.
Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Maclntyre F, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 46–58.
Reddy A, Heimbach T, Freiwald S, Smith D, Winters R, Michael S, et al. Validation of a semi-automated human hepatocyte assay for the determination and prediction of intrinsic clearance in discovery. J Pharm Biomed Anal 2005; 37: 319–26.
Wilkinson GR . Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211–21.
Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004; 32: 1434–45.
Li W, Liu Y, He YQ, Zhang JW, Gao Y, Ge GB, et al. Characterization of triptolide hydroxylation by cytochrome P450 in human and rat liver microsomes. Xenobiotica 2008; 38: 1551–65.
Kim AR, Lim SJ, Lee BJ . Metabolic inhibition and kinetics of raloxifene by pharmaceutical excipients in human liver microsomes. Int J Pharm 2009; 368: 37–44.
Shin HS, Bae SK, Lee MG . Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects. Int J Pharm 2006; 320: 64–70.
Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir — boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006; 43: 1347–56.
MacGregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, McCallister S . Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials 2004; 5: 371–82.
Li F, Wang L, Guo GL, Ma X . Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos 2010; 38: 871–8.
Scott JD . Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients. Am J Health Syst Pharm 2005; 62: 809–15.
Acknowledgements
This study was supported by Chinese National Science & Technology Major Special Project on Major New Drug Innovation (2009ZX09102-008) and by a grant from the Beijing Municipal Science and Technology Commission (D0206001040191). We thank Dr Yao-qiu ZHU of MetabQuest Co for his generous assistance with metabolite identification.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhuang, Xm., Deng, Jt., Li, H. et al. Metabolism of novel anti-HIV agent 3-cyanomethyl-4-methyl-DCK by human liver microsomes and recombinant CYP enzymes. Acta Pharmacol Sin 32, 1276–1284 (2011). https://doi.org/10.1038/aps.2011.91
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2011.91
Keywords
This article is cited by
-
A concise access to bridged [2,2,1] bicyclic lactones with a quaternary stereocenter via stereospecific hydroformylation
Nature Communications (2021)
-
PQ-69, a novel and selective adenosine A1 receptor antagonist with inverse agonist activity
Purinergic Signalling (2014)
